Cell & Gene Therapy Manufacturing Services Market Report 2022: Rising Investment in Pharmaceutical R&D - ResearchAndMarkets.com

[ad_1]

DUBLIN–(Business Wire)–“Cell and Gene Therapy Manufacturing Services Market Analysis by Type, Indication, Application, End User and Region – Global Forecast to 2029” report has been added. of ResearchAndMarkets.com An offering.

The market size of cell and gene therapy manufacturing services industry is estimated to be USD 8.4 billion by 2021 and is expected to grow at a CAGR of 14.56% during the forecast period 2022-2029. rising rates of cancer and other target diseases; increased investment in pharmaceutical R&D; CDMOs’ investments in advanced technologies; Increasing partnerships and contracts between pharmaceutical companies and CDMOs are some of the key drivers for market growth.

However, Increasing operational costs of cell and gene therapy manufacturing is expected to restrain market growth.

By category

Based on type, the market is bifurcated into gene therapy and cell therapy. By 2021, mesenchymal stem cells; dendritic cells and T-cells; The cell therapy segment accounted for the largest revenue share due to the development of new technologies and product innovations that allow a variety of cells, including hematopoietic stem cells (HSC). natural killer cells; To cure illnesses and diseases.

By pointing

Based on indication, the market is divided into central nervous system disorders; Ophthalmology cardiovascular diseases; infectious diseases; bone diseases Classified as cancer and others. In 2021, the infectious diseases segment accounted for the largest revenue share due to the expansion of cell therapy clinical trials due to rising prevalence of infectious diseases.

By application

Based on application, the market is segmented into commercial manufacturing and practical manufacturing. By 2021, The pharmaceutical manufacturing segment will account for the largest revenue share in 2021 due to gene therapy clinical trials and the continuous expansion of the global pipeline of cell and gene therapies.

by the user

on a per user basis; The market is categorized into academic and research institutions and pharmaceutical and biotechnology companies. By 2021, The academic and research institutes segment accounts for the highest share in 2021 due to increased government funding for research and rising expenditure in the R&D sector in life sciences.

Regional markets

By 2021, The North American region accounts for the highest revenue in the cell and gene therapy manufacturing services market and is expected to maintain its dominance during the forecast period. This is attributed to rising cancer prevalence and increasing research efforts in cancer and stem cells, while significant investments in biopharmaceutical research and development are fueling the market growth. Also, rising investment in pharmaceutical research and development is accelerating regional market expansion.

Segmentation: Cell and Gene Therapy Manufacturing Services Market Report 2021-2029

By Category (Revenue, USD Billion)

Gene therapy

Cell therapy

By indicator (revenue, billion USD)

Central nervous system disorders

Eye diseases

Cardiovascular diseases

Infectious diseases

Bone diseases

Cancers

Others

By Application (Revenue, USD Billion)

Commercial tax

Practical production

By User (Revenue, USD billion)

Academic and research institutes

pharmaceutical and biotechnology companies

By Region (Revenue, US$ Billion)

North America

Europe

Germany

France

UK

Spain

Italy

The rest of Europe

Asia Pacific

China

Japan

India

Australia

South Korea

Rest of APAC

Latin America

Brazil

Mexico

Argentina

Rest of LATAM

Middle East and Africa

South Africa

GCC

The rest of the MEA

Key topics include:

1. Research methodology

2. Introduction: Cell and Gene Therapy Manufacturing Services

3. Executive Summary

4. Market Dynamics

5. Market environment analysis.

6. COVID-19 Impact Analysis: Cell and Gene Therapy Manufacturing Services Market

7. Market analysis by category.

8. Market analysis by indication.

9. Market analysis by application.

10. Market Analysis by User.

11. Regional Market Analysis.

12. North America Cell and Gene Therapy Manufacturing Services Market

13. Europe Cell & Gene Therapy Manufacturing Services Market

14. Asia Pacific Cell & Gene Therapy Manufacturing Services Market

15. Latin America Cell & Gene Therapy Manufacturing Services Market

16. MEA Cell & Gene Therapy Manufacturing Services Market

17. Competitor Analysis.

18. Company Profiles

19. Conclusion and Recommendations

The companies mentioned.

Thermo Fisher Scientific Inc. (US)

Merck KGaA (Germany)

Charles River Laboratories (USA)

Lonza (Switzerland)

Catalent Inc. (USA)

WuXi AppTec (China)

Takara Bio Inc. (Japan)

NIKON Corporation (Japan)

FUJIFILM Holdings Corporation (Japan)

F. Hoffmann-La Roche Ltd. (Switzerland)

Oxford Biomedica plc (UK)

Cell and Gene Therapy Catapult (UK)

Discovery Labs LLC (US)

RoslinCT (Scotland)

JRS PHARMA (Germany)

FinVector (Finland)

ABL Inc. (USA)

Endurance (US)

BioCentriq (USA)

Porton Biopharma Limited (England)

Elyn Biosciences (USA)

Commercial Biological Remedies (Canada)

Vibalogics (USA)

Anemocyte Srl (Italy)

ElevateBio (USA).

For more information on this report, visit https://www.researchandmarkets.com/r/tflydy.